Navigation Links
AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
Date:7/29/2010

ALISO VIEJO, Calif., July 29 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that it will release unaudited fiscal third quarter financial results for the three and nine months ended June 30, 2010 before market open on Thursday, August 5, 2010.  Keith Katkin, President and Chief Executive Officer, Randall Kaye, M.D., Senior Vice President and Chief Medical Officer, and Christine Ocampo, Vice President, Finance, will host an investment community conference call that same day at 8:00 a.m. Pacific time / 11:00 a.m. Eastern time to discuss those results and answer questions.

Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com.  To listen to the live call, please go to AVANIR's website prior to the start of the call to register, download and install the necessary audio software.

An archived copy of the webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through August 10, 2010, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 90500390.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.  As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.  For more information about AVANIR, please visit www.avanir.com.  


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... of Cynosure, Inc., a leader in medical aesthetics systems ... "We are pleased to complete our acquisition of ... Davin and the entire Cynosure team to achieve ... aesthetics market," said Steve MacMillan , Hologic,s Chairman, ...
(Date:3/22/2017)... 2017 FinancialBuzz.com News Commentary ... industry is strongly contributing to job creation. A recent ... reporting for the cannabis industry, projects that by 2020, ... quarter million jobs for American workers. The legal cannabis ... and is projected to grow at a compound annual ...
(Date:3/22/2017)... , March 22, 2017   Upsher-Smith Laboratories, Inc . ... USP, 25 mg, 50 mg and 75 mg, the generic ... USP. The clomipramine hydrochloride capsules market had ... ending December 2016, according to IMS Health. ... "Upsher-Smith has long been ...
Breaking Medicine Technology:
(Date:3/23/2017)... Washington, DC (PRWEB) , ... March 23, 2017 , ... ... for Dental Choice has helped score a major victory in Europe for public health ... lead. , Based on rigorous scientific research and the overwhelming support of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of ... expression in circulating tumor cells using microfluidic western blotting” in Nature Communications on ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western blot ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... and this tool bypasses that. Healthcare facilities across the country are always ... offer their clients and hospitals, across the country, an efficient and quick way ...
Breaking Medicine News(10 mins):